文拉法辛和其他药物在偏头痛中的比较有效性:一项元分析与试验序列分析
Ju Gao1,2, Guang Ming Xia1,2, Xiang Bo Wu1,2
1Department of Neurology, Huanggang Central Hospital of Yangtze University, Huanggang, China.
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
|November 17, 2025
概括
文拉法辛有效地预防偏头痛,显著减少疼痛和频率. 然而,需要更多的研究来证实它对头的益处,需要额外的患者才能获得明确的结果.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 偏头痛是一种流行的神经系统疾病,影响全球数百万人.
- 有效的预防性治疗对于管理偏头痛的频率和严重程度至关重要.
研究的目的:
- 评估文拉法辛在偏头痛预防方面的疗效.
- 使用元分析和试验序列分析 (TSA) 评估文拉法辛对各种偏头痛相关结果的影响.
主要方法:
- 从开始到2024年11月1日进行了系统的数据库搜索.
- 进行了对8项涉及582名患者的研究的元分析.
- 使用试验顺序分析 (TSA) 来评估研究结果的可靠性.
主要成果:
- 文拉法辛的整体疗效优于其他药物 (OR = 18.71,p = 0.0008).
- 在视觉模拟量表得分,偏头痛日,头障碍库存 (DHI) 得分,的严重程度和止痛药的使用中观察到显著的减少.
- TSA指出,对的改善没有足够的证据,需要另外372名患者.
结论:
- 文拉法辛作为有效的偏头痛预防药物表现有前途.
- 虽然文拉法辛在有效性和安全性方面具有优势,但需要进一步的大规模研究来验证,特别是对于头的结果.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
784
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
784
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
1.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.3K
Antidepressant Drugs: Overview
1.4K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.4K
Bioequivalence of Drugs: Drugs with Multiple Indications
144
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
144
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
581
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
581
Electroconvulsive Therapy
835
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
835


